Company Filing History:
Years Active: 2018
Title: Marja Steenman: Innovator in Biomarkers of Mineralocorticoid Receptor Activation
Introduction
Marja Steenman is a notable inventor based in Nantes, France. She has made significant contributions to the field of medical research, particularly in the area of biomarkers related to mineralocorticoid receptor activation. Her work has implications for predicting patient responses to specific treatments.
Latest Patents
Marja Steenman holds a patent for her invention titled "Biomarkers of Mineralocorticoid Receptor Activation." This invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers for mineralocorticoid receptor activation in patients. The method she developed involves determining the expression levels of the NGAL gene and/or the SERPINA3 gene in biological samples from patients. This innovation is crucial for predicting how patients will respond to treatments involving MR antagonists or aldosterone synthase inhibitors.
Career Highlights
Throughout her career, Marja has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Inserm. Her research has been pivotal in advancing our understanding of mineralocorticoid receptor activation and its clinical implications.
Collaborations
Marja has collaborated with prominent researchers in her field, including Frederic Jaisser and Nicolette Farman. These collaborations have enriched her research and contributed to the development of her innovative patent.
Conclusion
Marja Steenman's work in the field of biomarkers for mineralocorticoid receptor activation showcases her dedication to advancing medical research. Her patent represents a significant step forward in predicting patient treatment responses, highlighting her impact on the scientific community.